42 results
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
10 Apr 24
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
8:50am
to certain side effects in current standard care solutions that use antiseptic agents and materials, such as allergies. These standard care solutions may
424B5
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Prospectus supplement for primary offering
4:01pm
solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate
6-K
EX-10.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager
8:46am
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including … , releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
12 Mar 24
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
4:01pm
materials will significantly reduce manufacturing costs and eliminate the global dependence on a single raw material supplier.
Inspira Technologies OXY … exchange facilitation technologies and that transitioning from fiber membrane to alternative materials will significantly reduce manufacturing costs
6-K
EX-99.1
5x3k3bdr
8 Mar 24
Notice of Extraordinary General Meeting of Shareholders
4:01pm
6-K
EX-99.1
57uklh
4 Mar 24
Notice of Extraordinary General Meeting of Shareholders
4:01pm
424B5
6j90s ff6a0vja
28 Dec 23
Prospectus supplement for primary offering
9:28am
6-K
EX-10.1
e7141
27 Dec 23
Inspira Announces $3.88 Million Registered Direct Offering
4:46pm
6-K
EX-99.1
ecapykx
26 Dec 23
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
4:01pm
6-K
EX-99.1
khcav c5whq
22 Nov 23
Notice of Annual General Meeting of Shareholders
4:01pm
POS AM
tpo a5merkggd
10 Oct 23
Prospectus update (post-effective amendment)
5:00pm
6-K
EX-99.2
2unzubdx2 w1ne
2 Oct 23
Interim Condensed Financial Statements
4:01pm
20-F/A
6nxtih
19 Apr 23
Annual report (foreign) (amended)
5:42pm
6-K
EX-1.1
gh37 f9ucp
4 Apr 23
Report of Foreign Private Issuer
4:21pm
424B5
8jmie7l39dt39jw772e
4 Apr 23
Prospectus supplement for primary offering
4:19pm
POS AM
d0mqy20b2 b7gf
13 Oct 22
Prospectus update (post-effective amendment)
4:01pm
6-K
EX-99.2
7u1bqlh25s37eo
29 Sep 22
Interim Condensed Financial Statements
2:33pm
6-K
EX-99.1
rkvh mk5fyqbz
8 Sep 22
Notice of Annual and Extraordinary General Meeting of Shareholders
4:01pm